A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470
This study is recruiting at 7 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion in Module A of the study. Combination therapy with pembrolizumab will occur in Module B of the study Participants will receive vobramitamab tavatecan by intravenous (IV) infusion. The dose of vobramitamab tavatecan will be assigned at the time of enrollment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumor
- Advanced Cancer
- Metastatic Cancer
- Squamous Cell Carcinoma of Head and Neck
- Non Small Cell Lung Cancer
- Small-cell Lung Cancer
- Bladder Cancer
- Sarcoma
- Endometrial Cancer
- Melanoma
- Castration Resistant Prostatic Cancer
- Cervical Cancer
- Colorectal Cancer
- Gastric Cancer
- Gastro-esophageal Cancer
- Pancreas Cancer
- Clear Cell Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Platinum-resistant Ovarian Cancer
- Breast Cancer
- Ovarian Cancer
- Esophageal Squamous Cell Cancer (SCC)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- MacroGenics
- Last updated on ClinicalTrials.gov
- October 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- The Angeles Clinic and Research Institute · Los Angeles, CA
Michigan · 1
- START Midwest · Grand Rapids, MI
New York · 1
- START-New York Long Island · Lake Success, NY
Oregon · 1
- Providence Cancer Institute · Portland, OR
Texas · 2
- The University of Texas MD Anderson Cancer Center · Houston, TX
- University of Texas Health Science Center at Houston · Houston, TX
Utah · 1
- START Mountain Region · West Valley City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.